Fatty Liver Disease and Gut Microbiota: A Comprehensive Update
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver in the absence of secondary causes. NAFLD is a multifactorial disease that results from the interaction of genetic predisposition and metabolic, inflammatory and environmental factors. Among these factors, dysregulation of gut microbiome has been linked to the development of fatty liver disease. The microbiome composition can be modified by dietary habits leading to gut microbiome dysbiosis, especially when a diet is rich in saturated fats, animal products and fructose sugars. Different species of bacteria in the gut metabolize nutrients differently, triggering different pathways that contribute to the accumulation of fat within the liver and triggering inflammatory cascades that promote liver damage. In this review, we summarize the current understanding of the roles of gut microbiota in mediating NAFLD development and discuss possible gut microbiota-targeted therapies for NAFLD. We summarize experimental and clinical evidence, and draw conclusions on the therapeutic potential of manipulating gut microbiota to decrease the incidence and prevalence of fatty liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 4×
“However, until further data supports its effectiveness, vitamin E should not be considered a standard treatment of NASH in diabetic patients, NAFLD without liver biopsy, NASH cirrhosis, or cryptogenic cirrhosis.(1,38) Larger randomized controlled trials focusing on histological endpoints are necessary to precisely ass…”
BackgroundMethodInfluentialVrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · cited 2×
“It was determined that the prevalence of bacterial overgrowth is higher in obese patients than in lean controls and is associated with hepatic steatosis.(26) In other studies, patients with SIBO had increased expression of TLR4 and increased release of interleukin-8, which is associated with NAFLD.”
BackgroundComposition, variability, and temporal stability of the intestinal microbiota of the elderly
Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E., Marchesi, J. R., Falush, D., Dinan, T., Fitzgerald, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000097107 · Cited by 1,754
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708 · cited 3×
“Zhu et al.(24) studied ethanol blood alcohol levels in NASH patients who had not consumed any ethanol-containing beverages and compared the findings to non-NASH patients.”
BackgroundResultDumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601056103 · Cited by 1,042 · cited 1×
“Furthermore, as we noted before, Gram-negative bacteria contain lipopolysaccharides which promote chronic inflammation, metabolic dysfunction, insulin resistance, and diabetes.(13,34) In one study, mice that were bred to have a genetic predisposition to insulin resistance and NAFLD were fed a high-fat diet.”
BackgroundMicrobial conversion of choline to trimethylamine requires a glycyl radical enzyme
Craciun, S., & Balskus, E. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215689109 · Cited by 701
Raman, M., Ahmed, I., Gillevet, P. M., Probert, C. S., Ratcliffe, N. M., Smith, S., Greenwood, R., Sikaroodi, M., Lam, V., Crotty, P., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.015 · Cited by 672 · cited 6×
“The current gold standard for the management of NAFLD is weight loss and minimizing metabolic risk factors.(19) Data suggest that diet is the most important intervention to target NAFLD and NASH.”
BackgroundInfluentialLooking for a Signal in the Noise: Revisiting Obesity and the Microbiome
Sze, M. A., & Schloss, P. D. (2016) · mBio · doi:10.1128/mbio.01018-16 · Cited by 600 · cited 4×
“Additionally, a change in the ratio between bacteroidetes to firmicutes is often noted in studies in both obese and NAFLD groups.(21) A recent meta-analysis by Sze et al.”
BackgroundMethodInfluential
Cited by
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“Another theory suggest that gut microbiome alteration and dietary habits are another mechanism that induce and maintain T2DM and/or NAFLD [96, 97].”
BackgroundBeneficial Effects of Betaine: A Comprehensive Review
Arumugam, M. K., Paal, M. C., Donohue, T. M., Ganesan, M., Osna, N. A., & Kharbanda, K. K. (2021) · Biology · doi:10.3390/biology10060456 · Cited by 291
Macrophages in metabolic associated fatty liver disease
Alharthi, J., Latchoumanin, O., George, J., & Eslam, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i16.1861 · Cited by 65
Bahrami, M., Cheraghpour, M., Jafarirad, S., Alavinejad, P., Asadi, F., Hekmatdoost, A., Mohammadi, M., & Yari, Z. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102452 · Cited by 60
The role of host molecules in communication with the resident and pathogenic microbiota: A review
White, J. R., Dauros-Singorenko, P., Hong, J., Vanholsbeeck, F., Phillips, A., & Swift, S. (2020) · Medicine in Microecology · doi:10.1016/j.medmic.2020.100005 · Cited by 21
Metadata
- Authors
- Campo, L., Eiseler, S., Apfel, T., & Pyrsopoulos, N.
- Venue
- Journal of Clinical and Translational Hepatology
- Publisher
- Xia & He Publishing
- Published
- 2018-12-28
- Volume
- 7
- Issue
- 1
- Pages
- 1-5
- ISSN
- 2225-0719 (ISSN-L)
- 2310-8819
- OpenAlex
- W2907146915
- Cited by
- 66
- References
- 16
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. https://app.cochat.ai/papers/10.14218/jcth.2018.00008
- The paper
- Campo, L., Eiseler, S., Apfel, T., & Pyrsopoulos, N. (2019). Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. Journal of Clinical and Translational Hepatology. https://doi.org/10.14218/jcth.2018.00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.